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Late complicationsIntroduction: The dose–volume effect of radiation therapy on breast tissue is poorly understood. We esti-
mate NTCP parameters for breast ﬁbrosis after external beam radiotherapy.
Materials and methods: We pooled individual patient data of 5856 patients from 2 trials including whole
breast irradiation followed with or without a boost. A two-compartment dose volume histogram model
was used with boost volume as the ﬁrst compartment and the remaining breast volume as second com-
partment. Results from START-pilot trial (n = 1410) were used to test the predicted models.
Results: 26.8% patients in the Cambridge trial (5 years) and 20.7% patients in the EORTC trial (10 years)
developed moderate-severe breast ﬁbrosis. The best ﬁt NTCP parameters were BEUD3(50) = 136.4 Gy,
c50 = 0.9 and n = 0.011 for the Niemierko model and BEUD3(50) = 132 Gy, m = 0.35 and n = 0.012 for
the Lyman Kutcher Burman model. The observed rates of ﬁbrosis in the START-pilot trial agreed well with
the predicted rates.
Conclusions: This large multi-centre pooled study suggests that the effect of volume parameter is small
and the maximum RT dose is the most important parameter to inﬂuence breast ﬁbrosis. A small value
of volume parameter ‘n’ does not ﬁt with the hypothesis that breast tissue is a parallel organ. However,
this may reﬂect limitations in our current scoring system of ﬁbrosis.
 2013 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 108 (2013) 293–298Radiation therapy (RT) has an established role in the manage-
ment of early stage breast cancer to improve loco-regional control
and overall survival [1]. However, a proportion of patients develop
RT related complications including breast ﬁbrosis, breast shrinkage
and telangiectasia, which contribute to physical and psychological
morbidity. Clinicians estimate the likelihood of a complication
based on published literature and personal experience. The Emami
et al. [2] seminal paper was among the ﬁrst to provide a compre-
hensive review of radiation tolerance for normal tissues, estimat-
ing the tolerance doses (TD5 and TD50) for whole, 2/3 and 1/3
organ irradiation. More recently, Quantitative Analyses of Normal
Tissue Effects in the Clinic (QUANTEC) articles summarised the
quantitative effects of RT dose and treatment volume on late nor-
mal tissue complications [3]. However, very few investigators have
studied the radiation dose–volume effect for breast tissue [4–6].The inﬂuence of RT dose on late normal tissue complications is
well established [7–9], however the effect of treated breast volume
is unclear with conﬂicting reports in the literature [10]. The large
EORTC 22881-10882 ‘‘boost versus no boost’’ trial reported higher
breast ﬁbrosis rates among patients treated with larger boost vol-
umes on univariate analysis [11]. These results were hypothesis
generating, consistent with a volume effect for breast ﬁbrosis.
Newer techniques aim to exploit a volume effect for breast tissue,
including partial breast irradiation (PBI) [12], simultaneous inte-
grated tumour bed boost (SIB) [13] and image guided RT (IGRT)
[14], with the aim of reducing late normal tissue complications.
As these techniques become part of routine practice, a better
understanding of the dose–volume effect of radiation on breast tis-
sue is required.
The normal tissue complication probability (NTCP) models can
be used to estimate dose–volume effect by predicting the probabil-
ity of a complication for a non-uniform irradiated organ. For the
modelling exercise, one requires a dataset with diverse dose and
volume data and a meaningful quantitative toxicity endpoint.
294 NTCP model for breast ﬁbrosisThe purpose of this study is to test the volume effect hypothesis
and quantify the effect of volume parameter by estimating the
NTCP model parameters for breast ﬁbrosis as measured by indura-
tion score. Fibrosis is a common sequela of breast RT and adversely
affects overall cosmesis, it can be assessed using a scoring system
and is likely to impact on patient physical and psychological well-
being [15]. Individual patient data from randomised controlled tri-
als (RCTs) provide the most robust data on RT dose and toxicity.
Additionally, pooling of data from different RCTs increases the
diversity of the dataset and the generalisation of results to the
wider population [16]. Hence, the individual patient data from
two large RCTs were pooled together: EORTC 22881-10882 ‘‘boost
versus no boost’’ trial [8,9] and the Cambridge Breast IMRT trial
[17,18]. To our knowledge, no other dataset of this magnitude
has previously been pooled for the purpose of NTCP modelling
for breast tissue.Materials and methods
Patient cohort and toxicity scoring
Cambridge Breast IMRT trial [17,18]: This single centre trial re-
cruited 1145 patients with invasive breast cancer (stage T1-T3N0-
1M0) or ductal carcinoma in situ who received breast conserving
therapy (BCT). All patients received 40 Gy in 15 fractions over
3 weeks to the whole breast followed by an electron tumour bed
boost of 9 Gy in 3 fractions over 3 days in selected cases
(n = 728). Breast ﬁbrosis was clinically assessed at 2 and 5 years
after completion of RT and scored on a four point scale (0 = none,
1 = a little, 2 = quite a bit (moderate) and 3 = very much
(severe)).
EORTC 22881-10882 ‘‘boost versus no boost’’ trial [8,9]: This
multi-centre trial recruited 5569 patients with invasive breast can-
cer (stage T1-T2N0-1M0) who received BCT. All patients received
50 Gy in 25 fractions over 5 weeks to the whole breast and were
randomised between no boost (n = 2657), 10 Gy in 5 fractions
boost (n = 126), 16 Gy in 8 fractions boost (n = 2661) and 26 Gy
in 13 fractions boost (n = 125). Electrons (63%), photons (29%)
and low dose rate brachytherapy (9%) were used to deliver the
boost dose. Breast ﬁbrosis was clinically assessed and scored on a
four point scale (1 = none, 2 = minor, 3 = moderate, and 4 = severe)
at every follow up visit.
The brachytherapy technique can lead to signiﬁcant dose heter-
ogeneity and its boost volumes are usually much smaller than
external beam techniques [19]. Hence, patients with brachyther-
apy boost were excluded from the analysis as were patients with
missing data/toxicity score (Cambridge trial: 571 and EORTC trial:
275).Dose–volume data
The accuracy with which NTCP model parameters can be esti-
mated depends on the quality of both the dosimetric information
and clinical follow up data. The late toxicity scores and boost vol-
umes were recorded in the trials but limited dose-distribution data
were available. Therefore, a more simplistic two-compartment
dose–volume histogram (DVH) model was used. The ﬁrst step of
the DVH was the tumour bed volume receiving whole breast dose
plus boost dose and the second step of the DVH was the remaining
breast volume (whole breast volume minus tumour bed volume)
receiving whole breast dose only.
Whole breast volume was only recorded in the Cambridge trial.
Hence, a Monte Carlo (MC) simulation method was used to gener-
ate breast volume data for the EORTC patients. The MC simulation
used the breast volume distribution from the Cambridge trial and
an acceptance–rejection test of boost/breast volume ratio between5–40% (the range of boost volume to breast volume ratio observed
in the Cambridge data). It was assumed that the distribution of
breast volume and boost/breast volume ratio in the EORTC trial
is the same as in the Cambridge trial.NTCP modelling
Two radiobiological models were used: Lyman Kutcher Burman
(LKB) model [20] and the Niemierko model [21]. Both models as-
sume that for whole or partial organ irradiation, the dose–response
curve follows a basic sigmoid shape. Full details of the mathemat-
ical modelling are given in appendix 1.Estimation of NTCP parameters with 95% conﬁdence interval
AMaximum Likelihood Estimation (MLE) method [22] was used
to ﬁnd the best ﬁt values of the model parameters (BEUD50 [bio-
logically equivalent uniform dose leading to 50% toxicity], c50/m
[steepness of the dose–response curve] and n [volume parameter]).
A n value closer to one suggests that the organ has a parallel archi-
tecture with a strong volume dependence whilst a value of n closer
to zero suggests that the organ has a serial architecture with no
volume dependence on late complication rate. A full sequential
parameter search was performed with the following parameter
constrains: BEUD3(0–150), n (0.01–1.0), c50 (0.5–3.0) and m
(0.1–0.8). The 95% conﬁdence intervals (CI) for the optimally ﬁt
parameters were obtained using the Proﬁle Likelihood Estimation
method [23].Goodness of ﬁt estimation
Results from the START-pilot trial [24] were used to indepen-
dently assess the goodness of ﬁt of the predicted NTCP models.
The START-pilot trial randomised 1410 patients into one of three
whole breast RT dose fractionations: 50 Gy in 25 fractions or
39 Gy in 13 fractions or 42.9 Gy in 13 fractions. Patients were also
sub-randomised for tumour bed boost to a dose of 14 Gy in 7 frac-
tions using electrons. Breast induration was clinically assessed at
annual follow-up and scored on a four point scale (0 = none,
1 = mild, 2 = moderate and 3 = marked {severe}). Summative data
on moderate and severe breast induration at ﬁve years were used
for all three whole breast dose fractionations with and without
boost for the goodness of ﬁt estimation. The goodness-of-ﬁt statis-
tic was obtained by calculating the Pearson chi-square statistic
(v2) from the observed and predicted rates of breast ﬁbrosis.
Results
Individual dose–volume and toxicity data of 574 patients (50%)
from the Cambridge trial and 5282 patients (95%) from the EORTC
trial were available for the NTCP modelling. 26.8% (154/574) pa-
tients developed moderate-severe breast ﬁbrosis by 5 years in
the Cambridge trial and 20.7% (1096/5282) patients developed
moderate-severe breast ﬁbrosis by 10 years in the EORTC trial.
The patient’s RT dose volume characteristics are summarised in
Table 1.
Using the MLEmethod, the best ﬁt NTCP parameters for the Nie-
mierko model were BEUD3(50) = 136.4 Gy, c50 = 0.9 and n = 0.011.
The 95% CI for parameters were BEUD3(50) = 132.8–140 Gy,
c50 = 0.84–0.97 and n = 0.01–0.03. For the LKB model, the best ﬁt
parameters were BEUD3(50) = 132 Gy, m = 0.35 and n = 0.012 with
95% CI of BEUD3(50) = 128.8–135.6 Gy, m = 0.326–0.374 and
n = 0.01–0.03. Both models imply that the risk of moderate–severe
breast ﬁbrosis is strongly associated with RT dose and the effect of
the volume parameter is small. Using an a/b of 3 Gy and n = 0.01,
EQD2 (the equivalent dose in 2 Gy per fraction) leading to 50%
Table 1
Dose–volume characteristics from the Cambridge and the EORTC dataset used for the NTCP model.
Number of patients Mean boost volume (range) Moderate–severe ﬁbrosis rates
Cambridge dataset (assessed at 5-year)
No boost 235 – 40/235 (17%)
Boost 339 161.2 (33.6–540 cc) 114/339 (33.6%)
EORTC dataset (cumulative incidence at 10 years)⁄
No boost 2656 – 341/2656 (12.8%)
P6 Gy to <10 Gy 6 238 (108–372 cc) 1/6 (16.7%)
10 Gy 117 204.7 (42–1176 cc) 28/117 (23.9%)
12 Gy 31 185.9 (48–606 cc) 11/31 (35.5%)
14 Gy 93 273.4 (48–735 cc) 23/93 (24.7%)
16 Gy 2257 209 (22–1386 cc) 635/2257 (28.1%)
>16 Gy to 620 Gy 39 193.1 (52–630 cc) 9/39 (23.1%)
26 Gy 83 198.5 (43–630 cc) 48/83 (57.8%)
* The NTCP parameter estimation was based on the actual tumour bed boost dose delivered and not on the intention to treat boost dose.
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Fig. 1. Lyman Kutcher Burman model – the probability of moderate–severe breast
ﬁbrosis versus biological equivalent dose using a/b of 3 Gy (BED3). The solid line is
based on the best ﬁt parameters (BED3 = 132 Gy and m = 0.35) and the dashed lines
are upper and lower 95% CI. The summative toxicity data of the three dose
fractionations ± boost at ﬁve years from the START pilot trial are plotted.
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Fig. 2. Niemierko model – the probability of moderate–severe breast ﬁbrosis versus
biological equivalent dose using a/b of 3 Gy (BED3). The solid line is based on the
best ﬁt parameters (BED3 = 136.4 Gy and c50 = 0.9) and the dashed lines are upper
and lower 95% CI. The summative toxicity data of the three dose fractiona-
tions ± boost at ﬁve years from the START pilot trial are plotted.
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81.8 Gy for the LKB and Niemierko model, respectively.
The observed rates of moderate–severe induration in the START
pilot trial were in good agreement with the predicted rates of ﬁbro-
sis using the LKB model (Fig. 1) and the Niemierko model (Fig. 2).
Using the Pearson chi-square test with 5 degrees of freedom, the v2was 0.053 (p = 0.95) for the LKB model and v2 was 0.058 (p = 0.95)
for the Niemierko model suggesting a good ﬁt of the models.Discussion
A better understanding of the dose–volume effect for breast tis-
sue is timely as many patients now receive non-uniform breast
irradiation in the form of accelerated PBI, SIB and risk adapted RT
[12,13,25,26]. The EORTC 22881-10882 trial breast ﬁbrosis nomo-
gram showed a strong association between RT dose and ﬁbrosis,
with large boost volumes as a prognostic factor on univariate anal-
ysis only [11]. The purpose of this study was to speciﬁcally look at
the volume effect by developing a predictive NTCP model. This was
approached by pooling individual data from two large prospective
trials (5856 patients), that offered robust information on RT dose,
boost volume and late toxicity.
Using the MLE method, the volume parameter ‘n’ was close to
zero for both the LKB model and the Niemierko model. This sug-
gests that for moderate–severe ﬁbrosis, the breast tissue behaves
as a serial organ and the maximum RT dose is most predictive of
the complication. The summative data of 1410 patients from an
independent dataset with six RT dose levels had a good ﬁt on both
the LKB and Niemierko models (Figs. 1 and 2).
Parameter correlation leads to uncertainty of parameter esti-
mates, independent of the size and diversity of the dataset [27].
An effective method to decrease the uncertainty is ﬁxing one or
more model parameters. Hence the a/b was ﬁxed as 3 Gy in the
study based on the previously published literature [24]. There is
no evidence to suggest the superiority of one model over another
[28]. However, similar values of the estimated parameters from
the two models strengthen the results of this study.
Three other studies have previously estimated the NTCP param-
eters for breast ﬁbrosis and these results are summarised in Table 2.
Borger et al. [4] model was based on 404 patients treated with WBI
(50 Gy in 25 fractions over 5 weeks) followed by low dose rate Irid-
ium-192 based tumour bed boost (15–25 Gy). BEUDwas calculated
using a/b of 2 Gy and repair half-time of 1.5 h. The implant posi-
tions were re-constructed on the available radiographs and dose–
volume calculations were performed. The best ﬁt NTCP parameters
in the study were TD50 = 72 Gy and n = 0.16 ± 0.04. Though infor-
mative, the model parameters were estimated from patients with
brachytherapy boost alone. It is not evident to compare parameters
generated from brachytherapy to external beam techniques due to
the difference in dose distribution and a possible different radiobi-
ological effect. For this reason, patients with brachytherapy boost
were excluded in the current study. Avanzo et al. [5] estimated
the best ﬁt parameters for the model using average dosimetric
parameters (prescription dose, fraction dose, median follow up
Table 2
Summarised results of the best ﬁt NTCP parameters for moderate-severe breast ﬁbrosis.
Number of patients BEUD3(50) c50 m n
Borger et al. [4] 404 NTD50 = 72 Gy
(a/b = 2 Gy)
(t1/2 = 1.5 h)
0.16
Alexander et al.* [6]
LKB model 1546 104 Gy – 0.27 0.78
Relative seriality model 104 Gy 1.47 (s = 0.12)
Avanzo et al.* [5]
With repair correction ((t1/2 = 4.4 h) 2562 105.8 Gy – 0.22 0.15
Without repair correction 107.2 Gy 0.22 0.06
Current study
LKB model 5856 132 Gy 0.35 0.012
Niemierko model 136.4 Gy 0.9 0.011
NTD: Normalised total dose.
BEUD3(50): Biologically equivalent uniform dose using a/b of 3 Gy.
c50/m: Slope of the dose response curve.
n: Volume parameter.
t1/2: Repair half-time.
s: Describes the serial/parallel architecture of the organ. A value closer to 1 indicates a serial structure and a value closer to 0 indicates a parallel structure.
* These studies used summative dosimetric and toxicity data.
296 NTCP model for breast ﬁbrosisand dose–volume data) from three WBI studies without boost and
four external beam PBI studies. Three PBI studies used twice daily
fractionation, and BEUD calculations included a repair half-time of
4.4 h in the model. As the median follow up of the PBI studies was
short (1.3–4.2 years), a latency function correction was included.
The parameters were estimated using weighted least square meth-
od, with the number of patients in each dataset as weights. The
parameters for moderate-severe breast ﬁbrosis model were
BEUD50 = 105.8, n = 0.15 and m = 0.22. The authors acknowledged
that the gold standard approach to estimate NTCP parameters is
the use of individual dosimetric data/clinical outcome. MLE meth-
od based parameter estimates are also more precise as compared
to weighted least square method [29].
On the contrary, Alexander et al. [6] reported a strong effect of
volume parameter on breast ﬁbrosis. This study included summa-
tive data of 806 patients from the START- pilot trial [24], 590 pa-
tients from a Germany study [30] and 150 post-mastectomy
patients treated during the 1960s [31]. All patients received WBI
and no partial volume data were available for the ﬁtting analysis.
The dose–volume data were generated using an anthropomorphic
phantom and parameters were estimated for a relative seriality
model and Lyman model. The study suggested a parallel architec-
ture for breast tissue with a strong volume effect on breast ﬁbrosis
(n = 0.78). However, these results cannot be generalised for several
reasons:
(a) The study did not make allowance for the tumour bed boost
doses (additional RT dose) in the models.
(b) The toxicity outcome used is different between the studies.
The START-pilot and German study assessed breast ﬁbrosis
on clinical examination, whereas the post-mastectomy
study scored ﬁbrosis on photographs.
(c) The planning techniques for post-mastectomy study (1960s)
would be considered as outdated by present standards. One
would also expect different NTCP parameters for breast
ﬁbrosis after BCS and tissue ﬁbrosis after mastectomy.
(d) The study corrected time latency in BCT study (START-pilot
& German) based on the results of the historic post-mastec-
tomy series.
Overall, most studies have indicated a small volume effect for
breast ﬁbrosis. There are several possible reasons to explain the
difﬁculty in demonstrating the effects of volume parameter for
breast ﬁbrosis. Breast ﬁbrosis may represent a focal RT effect, withthe maximum RT dose as the most predictive factor. It is also pos-
sible that our current scoring methods for breast ﬁbrosis are not
sensitive to the volume effect. Breast ﬁbrosis is often graded as
mild-severe based on the severity; however the scoring system
does not take into account the extent of ﬁbrosis i.e. small discrete
region of ﬁbrosis and widespread region of ﬁbrosis are potentially
scored alike. It has been suggested that NTCP parameters are inﬂu-
enced by the severity of measured toxicity [32]. For rectum, Ranc-
ati et al. estimated the best ﬁt ‘n’ parameter was 0.23 forPgrade 2
rectal bleeding, which decreased to 0.06 when only severe rectal
bleeding (grade 3) was considered [32]. It is plausible that a vol-
ume effect for breast tissue may have been seen for mild ﬁbrosis,
but this endpoint was considered to be of less clinical signiﬁcance.
Apart from RT parameters, breast ﬁbrosis can also be inﬂuenced by
surgical techniques [33] and systemic therapy [34], which are not
accounted for in the mathematical model.
There is a need to investigate quantitative methods, which de-
ﬁne both the severity and extent of breast ﬁbrosis. The use of pa-
tient-reported toxicity scoring for NTCP modelling may also be
useful. A small area of ﬁbrosis in the breast may not be perceived
as toxicity by the patient, whereas a large area of ﬁbrosis in a small
breast is likely to be considered as signiﬁcant toxicity by the pa-
tient. Hence, patient-reported breast ﬁbrosis scoring may be more
sensitive to the change in treatment volume. Other toxicity end-
points like photographic assessed breast shrinkage may also be
more sensitive to the volume effect as it represents global organ ef-
fect, is more objective and scored independent of surgical changes.
The current study focused on breast ﬁbrosis as photographic
assessment and patient reported scoring were not available for
the majority of the patients included in the study [35,36].Limitations
It is recognised that there are several limitations of this study.
One of the intrinsic difﬁculties in modelling for breast tissue is
the lack of detailed dosimetric data. A two-compartment DVH
was used with the assumption that a homogeneous dose was
delivered to the breast during WBI. The EORTC whole breast vol-
ume data were generated using MC simulation, using parameters
from the Cambridge trial. It is clear that using simulated data for
the EORTC patients can lead to large uncertainties. A plot of boost
volume against moderate–severe ﬁbrosis suggests that the volume
effect is likely to be weak (Appendix Fig. 3) and the model param-
eters will not be affected by the distribution of the simulated
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ume datasets were generated for the EORTC patients using the
MC method. Furthermore, the variance of the ﬁrst two simulated
datasets was changed by 0.5 and 2 times the original value. Repeat
simulations and changing the variance of breast volume distribu-
tion did not signiﬁcantly change the estimated NTCP parameters
(in keeping with weak volume effect). Simulation techniques are
a powerful tool for modelling exercise. However, when applying
simulated parameter from one population to the outcome data of
another population, it is assumed that the two populations are
identical. This may not be true in all cases.
Other limitations of the study include the use of both photons
and electron boost modalities without any correction for their dif-
ferent radiobiological effectiveness (RBE). Bentzen et al. [37] previ-
ously reported RBE for electrons was 0.88 relative to photons at
4.1 mm depth. As the RBE difference at depths other than
4.1 mm is unknown, no attempts were made to correct for this.
The duration of follow up was different between the EORTC
(10 years) and Cambridge datasets (5 years). However, no suitable
adjustment could be made in the MLE method for latency. In addi-
tion, current literature indicates that the majority of the breast
ﬁbrosis events take place by ﬁve years time point [11]. For this
analysis, the score for ﬁbrosis was used independent from the site
in the breast (boost area or elsewhere). It is not expected to inﬂu-
ence on our results, as it is most often located at the boost area
(where the highest dose is given). Moreover, the worst score ever
was reported. Although improvement of ﬁbrosis is not expected,
erroneous scoring of oedema early after treatment might be possi-
ble. Large breast volume has been reported as an independent risk
factor for breast shrinkage and change in breast appearance
[38,39]. However, one of the inherent limitations with NTCP mod-
elling exercise is that it is driven by partial dose volume data, inde-
pendent of whole organ volume. Apart from dose volume
parameter, other patient (smoking, diabetes), treatment (type of
surgery, chemotherapy, endocrine therapy and post-operative
complications) and genetic factors also inﬂuence on breast ﬁbrosis
[11]. These factors were not available for the analysis in the current
study.
Conclusions
This large multi-centre pooled study suggests that the effect of
volume parameter is small and the maximum RT dose is the most
important parameter to inﬂuence late breast ﬁbrosis. However,
this may reﬂect limitations in our current scoring system. Other
RT associated complications should also be analysed to determine
the effects of dose–volume parameters and patient-reported out-
comes should complement clinician score-based models in the fu-
ture. Inclusion of other clinical factors is desirable for future NTCP
modelling work.
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